The Efficacy and Safety of Mainstream Medications for Patients With cDMARD-Naïve Rheumatoid Arthritis: A Network Meta-Analysis

The Efficacy and Safety of Mainstream Medications for Patients With cDMARD-Naïve Rheumatoid Arthritis: A Network Meta-Analysis

Background: The mainstream medications for rheumatoid arthritis (RA) include conventional disease-modifying antirheumatic drugs (cDMARDs), which mostly are methotrexate (MTX), and biologic agents such as adalimumab (ADA), certolizumab (CZP), etanercept (ETN), golimumab (GOL), infliximab (IFX), and t...

Full description

Bibliographic Details
Main Authors: Weiyan Cai, Youyi Gu, Huanqin Cui, Yinyin Cao, Xiaoliang Wang, Yi Yao, Mingyu Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-03-01
Series:Frontiers in Pharmacology
Subjects:
rheumatoid arthritis
DMARDs
safety
efficacy
network meta-analysis
Online Access:http://journal.frontiersin.org/article/10.3389/fphar.2018.00138/full

Internet

http://journal.frontiersin.org/article/10.3389/fphar.2018.00138/full

Similar Items